Policies
141 Class II Devices Proposed to UDI Starting June 1, 2024
NMPA proposed 141 Class II devices to be subject to UDI, according to “Implementation of the Third Batch of Medical Devices UDI” published on November 30, 2022. It asked manufacturers to prepare for UDI inclusion for three kinds of Class II devices: disposable products with large clinical demand, varieties included in the scope of medical insurance and medical cosmetic products.
The notice proposed that the above Class II devices manufactured after June 1, 2024, shall have unique identifiers. For our comprehensive please click HERE
Unapproved Breast Implant: DeneB Hyaluronic Acid’s First Injection in China
The DeneB hyaluronic acid, manufactured by South Korea’s BioPlus, completed the first injection in Hainan Lecheng Hospital on November 29, 2022.
The product was approved in several countries but not yet in China. Hainan Real World Data program provided a shortcut for BioPlus products to be launched in China. For more information on this product and Hainan RWD program, please click HERE
Guidelines & Standards
Recombinant Human Collagen Guideline Issued
NMPA released the “Review Key Points of Recombinant Human Collagen Injection Materials for Plastic Surgery (Draft)” on December 29, 2022, directing manufacturers on type test, preclinical testing, clinical evaluation, and regulatory submission.
Recombinant Human Collagen is a Class III device. The division of registration units should focus on factors such as the technical principle, structural composition, performance indicators and scope of application. For other highlights of the guideline, please click HERE
Seven IVD Guidelines Ask for Feedback
NMPA issued seven IVDs draft guidelines on December 2, 2022, soliciting public opinions. Affected devices include blood glucose monitoring system, gene mutations reagents associated with tumor individualized therapy, etc. For full list please click HERE
Fast-Track Approvals
Two Cardio Imaging Devices Gain Innovation Approval
NMPA granted innovation approvals to two radiology devices, used in combination for ultrasound imaging of intravascular lesions in coronary arteries. For more information on the two devices please click HERE
About China Med Device, LLC
China Med Device, LLC (www.ChinaMedDevice.com) provides regulatory and commercialization turnkey solutions for medical device, IVD, CDx and combination products in China. As a qualified NMPA legal agent with offices in Boston, Beijing and Hainan, we can represent manufacturers for the complete product life cycle without their need to create a local entity in China. Our regulatory services include strategy, registration, type testing, product technical requirement (PTR), clinical evaluation report (CER), clinical trial, GMP and post-market surveillance. Our commercialization services include market research, reimbursement, partnership strategy and distribution qualification.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
- Source: https://chinameddevice.com/nmpa-december-2022/
